Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial by SPRANGE, KIRSTY et al.
 1 
 
Gentamicin compared with Ceftriaxone for the treatment of gonorrhoea: a 
randomised trial (G-ToG Trial) 
 
Short title: Gentamicin for the Treatment of Gonorrhoea: G-ToG Trial 
 
Authors and affiliations: 
Authors: Jonathan DC Ross1, Clare Brittain2, Michelle Cole3, Claire Dewsnap4, Jan Harding1, Trish 
Hepburn2, Louise Jackson5, Matthew Keogh, Tessa Lawrence1, Alan A Montgomery2, Tracy E 
Roberts5, Kirsty Sprange2, Wei Tan2, Sukhwinder Thandi2, John White6, Janet Wilson7, Lelia Duley1 , 
on behalf of the G-ToG Trial Team 
1Birmingham University Hospitals, Birmingham, UK (Prof. JDC Ross (MD), J Harding (PhD), T 
Lawrence (PhD); 2Nottingham Clinical Trials Unit, University of Nottingham, Queen’s Medical 
Centre, Nottingham, UK (W Tan (MSc), Prof AA Montgomery (PhD), C Brittain (BMedSc), K 
Sprange (MSc) S Thandi (PhD), Prof L Duley (MD), T Hepburn (BSc),); 3Antimicrobial Resistance 
and Healthcare Associated Infections (AMRHAI) Reference Unit, Public Health England, London, 
UK (Michelle Cole (DBMS);4 Sheffield Royal Hallamshire Hospital, Sheffield, UK (Claire Dewsnap 
(MD)); 5Health Economics Unit, Institute of Applied Health Research, University of Birmingham, 
UK (L Jackson (PhD), Prof TE Roberts (PhD)); 6Guy’s and St Thomas’ NHS Foundation Trust, 
London, UK (Dr J White (FRCP); 7Leeds Teaching Hospitals NHS Trust, Leeds, UK (Dr J Wilson 
(FRCP)); Patient and Public Involvement representative, UK (M Keogh)  
 
Corresponding author: Professor Jonathan Ross, University Hospitals Birmingham NHS Foundation 
Trust, Whittall Street Clinic, Birmingham, UK, B4 6DH 
Tel: +44 (0)121 237 5721 
 
e-mail: jonathan.ross@uhb.nhs.uk 
 
  
 2 
 
Research in context 
Evidence before this study 
Two systematic reviews have evaluated the efficacy of gentamicin for the treatment of gonorrhoea. 
They included randomised trials, quasi randomised trials and prospective studies with concurrent 
controls published between 1950 and June 2014. A subsequent search of Medline and Embase using 
the terms “gonorrhoea/gonorrhea/Neisseria gonorrhoeae” and “gentamicin” was conducted for studies 
published from 2013 to 2017. In total, six studies evaluated single dose gentamicin treatment of which 
three were randomised trials, one was quasi-randomised and two were non-randomised. Cure rates of 
62% to 100% were reported with gentamicin treatment.  Methodology was poorly described and there 
was a high risk of bias within most studies. The largest and best quality study was a non-comparative 
evaluation of 157 patients, which reported that gentamicin cured 100% of infections. This study used a 
relatively less sensitive culture technique to diagnose gonorrhoea and assess cure, and included few 
extra-genital infections (ten pharyngeal, one rectal). Gentamicin was administered with a 2g dose of 
azithromycin. The combination regimen was poorly tolerated causing nausea in 26% of patients and 
vomiting in 10%. 
Added value of this study 
Due to antibiotic resistance, treatment options for gonorrhoea are diminishing. G-ToG is the first 
randomised trial to compare gentamicin with the current first line treatment, ceftriaxone, for 
gonorrhoea. The trial provides insufficient evidence to conclude the non-inferiority of gentamicin 
compared with ceftriaxone, as gentamicin was associated with a relatively high failure rate in patients 
with extra-genital infection. Cure rates for genital infection were similar between the two groups, 
however, so for these patients gentamicin may be useful second line therapy. Single dose gentamicin 
was safe and well tolerated.  
Implications of all the available evidence 
Ceftriaxone should remain the first line treatment for gonorrhoea, with gentamicin as an alternative 
particularly for patients with genital infection, and those who are allergic or intolerant to ceftriaxone, or 
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harbour ceftriaxone resistant gonococci. Further research is required to identify and test new 
alternatives to ceftriaxone for the treatment of gonorrhoea. 
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Abstract 
Background: Gonorrhoea is a common sexually transmitted infection for which ceftriaxone is the 
current first line treatment, but antimicrobial resistance is emerging. The objective of this study was to 
assess the effectiveness of gentamicin as an alternative to ceftriaxone (both combined with 
azithromycin) for treatment of gonorrhoea.  
 
Methods: We performed a blinded, non-inferiority randomised trial in 14 sexual health clinics in 
England. Adults with a diagnosis of uncomplicated genital, pharyngeal or rectal gonorrhoea were 
randomised using a secure web based system, stratified by clinic. Allocation was either to gentamicin 
240 mg or to ceftriaxone 500 mg, both administered as a single intramuscular injection. All participants 
also received 1 g oral azithromycin. The primary outcome was clearance of Neisseria gonorrhoeae at 
all infected sites. 
 
Findings: We enrolled 720 participants and randomly assigned them to gentamicin (n=358) or 
ceftriaxone (n=362), with 292 and 306, respectively, included in the primary analysis. Non-inferiority 
of gentamicin to ceftriaxone was not demonstrated (adjusted risk difference for microbiological 
clearance -6.4%, 95% CI -10.4%, -2.4%, NI margin -5%). Clearance of genital infection was similar in 
the two groups: 94% gentamicin versus 98% ceftriaxone: but for pharyngeal and rectal infections were 
lower in the gentamicin group (80% vs 96% and 90% vs 98%, respectively). The side effect profiles 
were comparable between the allocated groups, other than reported pain at the injection site, which was 
higher for gentamicin.  
 
Interpretation: Gentamicin is not an appropriate alternative first line treatment for gonorrhoea, but 
remains potentially useful for patients with isolated genital infection, or who are allergic/intolerant to 
ceftriaxone, or harbour a ceftriaxone resistant isolate. Further research is required to identify and test 
new alternatives to ceftriaxone for the treatment of gonorrhoea. 
Funding: NIHR Health Technology Assessment Programme 
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Introduction  
Each year gonorrhoea accounts for over 40,000 infections annually in the UK and around 78 million 
infections globally1, with a disproportionate burden in young adults, men who have sex with men 
(MSM), and specific ethnic groups. Infection leads to local inflammation causing genital pain and 
discomfort, and localized immune activation that facilitates the acquisition and transmission of HIV. 
For women, infection can spread to the fallopian tubes and ovaries causing pelvic inflammatory disease 
with resultant tubal scarring, infertility, chronic pelvic pain and an increased risk of ectopic pregnancy. 
In men, it can spread to the testicles leading to epididymo-orchitis, and for MSM it may involve the 
rectum causing proctitis that can lead to abscess and fistula formation.  
 
The causative organism, Neisseria gonorrhoeae, readily develops resistance to antibiotics. High-level 
resistance to penicillins, sulphonamides, tetracyclines and quinolones has led to these no longer being 
recommended as treatment. Current guidance is to treat with intramuscular ceftriaxone, given as dual 
therapy with azithromycin.2-4 Surveillance data in the UK show a reduction in susceptibility to 
ceftriaxone over time, with an upward drift in the minimum inhibitory concentration [MIC].1 A similar 
reduction in susceptibility for other antimicrobials used for gonorrhoea was followed within a few 
years by widespread treatment failure, and sporadic clinical failure of cephalosporins has been 
reported.5, 6 If ceftriaxone becomes ineffective, options for treatment are limited. With the exception of 
gentamicin, alternative agents have either not been assessed in vivo (e.g. ertapenem, 
piperacillin/tazobactam), are still in early development before licensing (e.g. zoliflodacin, gepotidicin), 
are reserved for other infections (e.g. rifampicin for tuberculosis), or have the potential for resistance to 
develop rapidly (e.g. azithromycin, spectinomycin). Untreatable, multi-drug resistant gonorrhoea is a 
real possibility, and new clinical trial data are needed to inform treatment guidelines.7 The World 
Health Organisation and European Centre for Disease Prevention and Control have called for urgent 
research into the efficacy of new regimens to treat gonorrhoea, including combination regimens and the 
assessment of antimicrobial efficacy at extra-genital sites.8, 9 There is a particular need for effective, 
safe and low cost treatment in low and middle income countries, many of which have a high burden of 
gonorrhoea infection. 
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Gentamicin is an aminoglycoside antibiotic that inhibits protein synthesis by irreversibly binding to 
30S ribosomal subunits. Studies in the 1970s/80s assessed gentamicin for gonorrhoea, but all were 
small and had a high risk of bias.10, 11 The dose used in these studies was usually 240 mg (range 160 
mg-5mg/kg) with no apparent dose response effect across studies, and no gentamicin associated 
adverse events were reported. In vitro susceptibility testing suggests that N. gonorrhoeae remains 
susceptible to gentamicin12 although the in vivo response and associated susceptibility breakpoints have  
been poorly characterised. Gentamicin can cause ototoxicity and nephrotoxicity13, but their frequency 
and severity following single dose therapy is not known.  
 
Recent systematic reviews report the clinical and microbiological cure rate with gentamicin for the 
treatment of gonorrhoea (mostly urogenital) to be 62-98%.10, 11 Data on its efficacy when treating 
pharyngeal or rectal gonorrhoea are scarce, although antibiotics for gonorrhoea are sometimes less 
effective at these sites.14 A recent large randomised non-comparative trial reported a cure rate of 100% 
when gentamicin was combined with 2 g oral azithromycin, but a high incidence of gastrointestinal 
adverse effects limited the tolerability of this regimen.15  
 
The aim of our study was to assess whether single dose gentamicin therapy is an acceptable alternative 
to (i.e non-inferior to) ceftriaxone for the treatment of gonorrhoea, when both antibiotics are combined 
with azithromycin. 
 
 
Methods 
Study design 
The G-ToG trial was a multi-centre, parallel group, blinded, pragmatic randomised trial comparing 
treatment with gentamicin versus ceftriaxone for patients with gonorrhoea. All participants also 
received 1 g oral azithromicin. The trial was conducted in 14 sexual health clinics in the UK. The 
protocol has been published,16 and is summarised here. The study was approved by Health Research 
Authority South Central – Oxford C Research Ethics Committee (14/SC/1030). The trial was registered 
prior to start of recruitment (ISRCTN51783227).  
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Participants 
Adults aged 16-70 years were eligible for participation if they had a diagnosis of untreated genital, 
pharyngeal and/or rectal gonorrhoea (i.e. had not received any antibiotic in the previous 28 days that 
could have treated gonorrhoea, either partially or completely). To reflect normal practice, all patients 
who had an initial positive test for gonorrhoea and presented for treatment were eligible for inclusion. 
Diagnosis was based on detection of intracellular Gram-negative diplococci by microscopy (urethral, 
cervical, vaginal or rectal specimens), or positive Nucleic Acid Amplification Test (NAAT) from first 
void urine, urethral, endocervical, vulvovaginal, pharyngeal or rectal swabs.  Any licensed NAAT test 
platform result was accepted for assessing eligibility for inclusion into the trial. Exclusion criteria were 
known concurrent bacterial sexually transmitted infection (apart from chlamydia); known bacterial 
vaginosis and/or Trichomonas vaginalis infection; known contra-indications or allergy to gentamicin, 
ceftriaxone, azithromycin or lidocaine; complicated gonorrhoea infection, for example pelvic 
inflammatory disease or epididymo-orchitis; and patient weight being less than 40 kg. Women who 
were pregnant or breast-feeding were also excluded. Participants were only eligible to participate in the 
trial once. They provided written informed consent at their initial consultation. 
 
Randomisation and blinding 
Participants were randomised to receive either intramuscular gentamicin 240 mg (intervention) or 
intramuscular ceftriaxone 500 mg (control). All participants also received 1 g oral azithromycin. 
Randomisation was in a 1:1 ratio, stratified by clinic and performed using a secure web-based system. 
We used a computer generated pseudo-random code with permuted blocks of randomly varying size 
created by the Nottingham Clinical Trials Unit (NCTU) in accordance with their standard operating 
procedure. The allocated treatment was administered from routine clinic stock. To maintain blinding, 
when a member of the research team randomised a participant, the system confirmed that 
randomisation had been successful but did not reveal the allocated treatment. An unblinded ‘injecting 
nurse’ who was trained only in the trial’s treatment administration procedure and not involved with any 
other trial procedures then logged onto the randomisation system to determine which treatment had 
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been allocated, and administered the injection and oral azithromycin. The ‘injecting nurse’ did not 
reveal the treatment allocation to participants, research staff or investigators, who all remained blinded. 
The allocation sequence remained concealed until the database was locked at the end of the trial. 
 
Procedures 
Ceftriaxone 500 mg in powder formulation was dissolved in 1% lidocaine and administered as a single 
2 ml intramuscular injection. Gentamicin 240 mg (3 x 80 mg in 2 ml vials) was administered as a 
single 6 ml intramuscular injection. In addition, all participants received a single oral dose of 1 g 
azithromycin. All participants were asked to avoid sexual contact until review after 2 weeks. 
 
Participants provided samples for N. gonorrhoeae testing before treatment. This varied by gender and 
sexual orientation: for heterosexual men – NAAT and culture testing from urethra (a first pass urine 
sample could be taken as an alternative to the urethra for NAAT); for men who have sex with men – 
NAAT and culture testing from urethra, pharynx and rectum (a urine sample could be taken as an 
alternative to the urethra for NAAT); for women – NAAT and culture testing from cervix, pharynx and 
rectum (a vaginal sample could be taken as an alternative to the cervix for NAAT). Follow up was two 
weeks after treatment, when NAAT and culture testing for N. gonorrhoeae was repeated for sites that 
had been positive at baseline. All baseline and post-treatment samples were required to be tested using 
NAAT (Hologic, Aptima Combo 2®). If the local laboratory did not use Aptima Combo 2® NAAT, 
additional samples were tested at Public Health England (PHE). Culture specimens were processed 
according to local laboratory procedures and pure viable cultures confirmed to be N. gonorrhoeae were 
frozen (≤-70oC) and shipped to PHE for antimicrobial sensitivity testing.  
 
Blood samples for creatinine measurement (allowing calculation of the estimated glomerular filtration 
rate) were taken at baseline and two week follow up attendances.  
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Outcomes 
The primary outcome was clearance of N. gonorrhoeae at all initially infected sites defined as a 
negative NAAT (Hologic, Aptima Combo 2®) two weeks post treatment.17 Analyses were performed 
without knowing the treatment allocation. Secondary outcomes were clinical resolution of symptoms, 
change in renal function (estimated glomerular filtration rate [eGFR]) and comparative cost 
effectiveness at two weeks. The relationship between clearance of N. gonorrhoeae and in vitro 
measurement of antibiotic minimum inhibitory concentration (MIC) using Etests (BioMérieux) on GC 
base agar (Becton Dickinson) with 1% Vitox (Oxoid) was also investigated. Safety outcomes were the 
frequency of known side effects (nausea/vomiting, hearing loss, dizziness and rash), frequency of any 
other adverse events reported by participants, and tolerability of the treatment injection measured on a 
visual analogue scale (VAS) where 0 represented no pain and 100 worst imaginable pain.  The results 
of the cost effectiveness analyses will not be presented in this paper. 
 
Statistical Analyses 
Based on 96% clearance for the ceftriaxone regimen, a total sample size of 646 (323 in each group) 
was required to detect non-inferiority with a lower confidence limit of 5% for the risk difference, with 
90% power and 0.025 one-sided significance. To allow for loss to follow-up of 10%, the trial had a 
target recruitment of 720 participants.  
 
All analyses were carried out using Stata/SE 13·1. The primary approach to between-group 
comparisons was to analyse participants according to randomised allocation without imputation of 
missing outcome data. Planned analysis of the primary outcome was modified, before the database was 
locked and treatment codes revealed. The initial analysis plan in the protocol was to use a general 
linear model for binary outcome adjusted by clinic site, with the primary efficacy parameter comparing 
gentamicin with ceftriaxone being the risk difference in the proportion of participants clear of infection 
at follow up along with the 95% confidence interval. However, additional clinics joined the trial, some 
of which recruited small numbers of participants. This meant that there was the chance that some 
clinics would have no participants whose infection had not cleared, making the inclusion of clinic as a 
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fixed effect inappropriate. Therefore, we modified the between-group comparative analyses to use 
generalised estimating equations (GEE) for binary outcomes adjusted by recruiting clinic as a random 
effect with robust standard errors. The GEE model used an identity link function to enable estimation 
of adjusted risk difference. Gentamicin was to be regarded as non-inferior if the lower 95% confidence 
limit for the risk difference (gentamicin group versus ceftriaxone group) in confirmed clearance was -5 
percentage points or greater (i.e. closer to zero). Analysis of the primary outcome included only 
participants who had follow up data and, since this was a pragmatic trial, included all participants 
meeting the trial entry criteria, irrespective of the baseline visit Neisseria gonorrhoeae test result.  
Sensitivity analyses were performed to assess the robustness of the primary outcome analysis including 
multiple imputation using chained equations; assuming all missing data were cleared and not cleared, 
excluding participants who did not have any positive baseline samples, excluding those who had not 
received their allocated treatment and excluding those who did not have a full set of baseline samples. 
 
Secondary outcomes were similarly analysed using appropriate regression models dependent on data 
type, adjusted for clinic site and baseline value of the outcome variable if collected. Clearance at each 
site was investigated separately for each infection site. MIC data were summarised on a per participant 
basis. The relationship between clinical effectiveness and MIC was examined by plotting the 
distribution of the highest MIC detected per participant categorised by clearance at all sites at two 
weeks. 
 
Safety and tolerability analyses were descriptive. Frequency counts and percentages of the pre-
specified main categories of side-effects were presented by treatment arm. Adverse events were coded 
using MedDRA version 17.1 and summarised by System Organ Class. 
 
Full details of the analysis are documented in the Statistical Analysis Plan, which was finalized prior to 
database lock and release of treatment allocation codes for analysis. An independent data monitoring 
committee oversaw the trial and were provided with unblinded data by treatment group, prepared by a 
statistician who was independent of the trial team. 
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Role of the funder 
The study was funded by the UK National Institute for Health Research (NIHR) Health Technology 
Assessment programme. The NIHR had input into trial design through peer review of the funding 
proposal. The funders did not have a role in data collection, data analysis, data interpretation or writing 
of the report but had sight of the paper prior to publication. The corresponding author had full access to 
all the data and had final responsibility for the decision to submit.  
 
Results 
Of 1762 patients approached at 14 sexual health clinics in England, 720 were randomised between 7 
October 2014 and 14 November 2016; 362 to receive ceftriaxone and 358 to receive gentamicin. The 
main reasons for non-randomisation were participants not being interested, the trial taking too much 
time, a belief that the standard treatment would be successful and the trial taking too many 
extra/intrusive samples.  Fourteen participants did not receive their allocated medication; four in the 
ceftriaxone group and ten in the gentamicin group (Figure 1). 96 participants did not return for their 
follow up visit – the reasons for 83 of these participants were unknown, and reasons for the others 
included withdrawal of consent, participants being found to be ineligible after randomisation, 
medication being out of stock and injecting nurses not being available. 26 participants who returned for 
their follow up visit did not have primary outcome data due to incorrect sampling. Primary outcome 
data were therefore available for 306 participants randomised to ceftriaxone (85%) and 292 participants 
randomised to gentamicin (82%). (Figure 1). 
 
The baseline characteristics of participants were well balanced across treatment groups (Table 1). 
Treatment groups appeared to be balanced with respect to participants’ history of sexually transmitted 
infections (41% had at least one previous diagnosis of gonorrhoea, 34% chlamydia, 14% syphilis, and 
for 3% of women pelvic inflammatory disease).  
Protocol deviations were reported in 121/362 (33%) of participants receiving ceftriaxone and 124/358 
35%) of those receiving gentamicin, the majority being considered minor.  Two major protocol 
deviations were identified - Not receiving treatment according to randomisation (14 participants – 4 
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randomised to ceftriaxone and 10 randomised to gentamicin) and not fulfilling eligibility criteria (18 
participants – 5 randomised to ceftriaxone and 13 randomised to gentamicin). (Supplementary Table 3).  
It was considered unlikely that the imbalance in the proportion of major protocol deviations was due to 
selection bias or knowledge of treatment allocation and that these violations did not impact on the 
validity of the trial. 
 
Overall 322/362 (89%) participants allocated to ceftriaxone and 302/358 (84%) allocated gentamicin 
attended their follow up visit. The median number of days from randomisation to follow up was 16 
(Q1-Q3 14-20) and 15 (Q1-Q3 14-20) in the ceftriaxone and gentamicin groups respectively. Most 
(82%) participants in both groups returned within 21 days.  
 
At two weeks post-treatment infection had cleared, as defined by a negative NAAT, for 299/306 (98%) 
participants allocated ceftriaxone compared to 267/292 (91%) allocated gentamicin; adjusted risk 
difference -6.4%, 95% CI -10.4% to -2.4% (Table 2). Sensitivity analyses were consistent with the 
primary analysis (Figure 2). 
 
Of the participants who had a genital infection, infection had cleared at follow up for 98% and 94% in 
the ceftriaxone and gentamicin groups respectively (Table 3). For participants with pharyngeal 
infection, a greater proportion receiving ceftriaxone had clearance at their follow up visit (96%) 
compared with gentamicin (80%). Similarly, a greater proportion of participants with rectal infection in 
the ceftriaxone group showed clearance (98%) compared with gentamicin (90%). There was no 
evidence of a clear difference between treatment groups in resolution of symptoms (Table 4).  
 
A similar proportion of participants experienced nausea in the ceftriaxone and gentamicin groups (12% 
vs 14%). Few participants experienced vomiting, reduction in hearing, dizziness/unsteadiness or skin 
rash, and proportions were similar in the two treatment groups. (Table 5). The majority reported 
injection site pain, 98% and 99% allocated ceftriaxone/azithromycin and gentamicin/azithromycin 
respectively, with the mean pain score measured using a visual analogue scale higher in the gentamicin 
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group (36/100 vs 21/100). The median time to resolution of injection pain was one hour for ceftriaxone 
and 1.5 hours for gentamicin. At least one adverse event (AE) was reported by 15% of participants 
allocated ceftriaxone and 13% allocated gentamicin, the majority of these were mild (45/54 ceftriaxone 
and 35/43 gentamicin). One serious adverse event (SAE) (grade 4 dizziness) was reported, and was not 
considered to be related to the trial medication. Changes in eGFR between baseline and follow up were 
similar in both arms (mean difference (-1.4 ml/min [IQR -6.9, 3.8]). In addition to the side effects 
participants were specifically asked about, 86 participants reported at least one other AE (48 receiving 
ceftriaxone and 38 gentamicin), most commonly gastrointestinal disorders (14 in the ceftriaxone group 
and 22 in the gentamicin group). More than 80% of AEs in each treatment arm were considered mild. 
Three AEs were considered severe (Table 5). 
 
There were no differences between treatment groups with respect to additional medications (including 
antibiotics) taken during the trial, reported sexual behaviour or condom use during the trial. 
 
We did not find a clear relationship between in vitro gentamicin, ceftriaxone or azithromycin MICs and 
the response to treatment, with the majority of treatment failures occurring in isolates expected to be 
susceptible according to EUCAST resistance breakpoints18 (Figure 3). 
 
 
Discussion 
Our study was unable to demonstrate that a single dose of gentamicin (240 mg) is non-inferior to single 
dose ceftriaxone (500 mg) for the treatment of gonorrhoea, when both drugs are combined with a 1g 
dose of oral azithromycin. The trial was not designed to assess superiority, but the 6.4% greater 
clearance of infection in the ceftriaxone group (lower 95% confidence limit 2.4%), and the consistency 
of the findings on sensitivity analyses, suggest that ceftriaxone is better than gentamicin for the 
microbiological cure of gonorrhoea. The failure to show non-inferiority appeared to be because 
gentamicin had markedly lower clearance rates in pharyngeal and rectal gonorrhoea, (-15.3% and -
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7.8% respectively). Gentamicin performed better for genital gonorrhoea, achieving microbiological 
cure in 94% of infections compared to 98% for ceftriaxone. 
 
Two systematic reviews 10, 11  have reported a wide variation in the efficacy of gentamicin for the 
treatment of gonorrhoea and noted a significant risk of bias in previous studies. A more recent study 
evaluating intramuscular gentamicin (240 mg) combined with oral azithromycin (2 g) reported a cure 
rate of 100% (lower 95% CI 97.6%).15 This study differed from GToG by using culture to diagnose 
gonorrhoea, using a 2g dose of azithromycin, involving few women, and including only a small 
number of participants with pharyngeal and rectal infections. The large number of extra-genital 
infections included in G-ToG, with their associated lower cure rate, provides a partial explanation for 
the difference in treatment efficacy reported in the two studies. 
 
Azithromycin as a component of dual therapy 
The use of dual therapy with azithromycin 1g did not prevent treatment failure occurring in a 
significant proportion of participants receiving gentamicin.  Azithromycin monotherapy has previously 
been shown to be effective treatment for gonorrhoea using a single dose of either 1 g or 2 g19 when 
culture is used to diagnose infection and assess cure. A reduction in in vitro sensitivity to azithromycin 
has been reported in many geographical locations20, 21 and occurs in 5% of infections in England and 
Wales,1 including a recent outbreak of high level resistance.22  The large majority of gonococcal 
isolates from participants in GToG (262/274[96%]) had azithromycin MICs of ≤ 0.5 mg/L. Of the 12 
azithromycin resistant isolates (MIC > 0.5 mg/L), 2 (17%) were from patients who had treatment 
failure, but the majority of failures (11/16[69%]) occurred in participants who had isolates with an MIC 
≤ 0.25 mg/L, with the remaining 3 isolates harbouring azithromycin MICs of 0.5 mg/L (intermediate 
susceptibility). Thus, we found in vitro azithromycin resistance did not reliably predict treatment 
failure with the 1 g azithromycin dose if we assume gentamicin failed to treat. However, further 
investigation into the relationship between azithromycin MICs and treatment failure is warranted. A 
poor association between pre-treatment azithromycin MIC and cure has been reported by others, with 
emergence of in vivo resistance.23, 24 A higher dose of azithromycin than that used in GToG (e.g. 2 g)15 
might be more effective but without a direct comparative study this is speculative, and a 2 g dose is 
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also poorly tolerated leading to nausea in 26% and vomiting in 10% of patients.15 An extended-release 
formulation of azithromycin which has lower peak drug levels might reduce the incidence of side-
effects and improve tolerability but there are limited data comparing it directly with the immediate-
release formulation.  
 
Current UK, CDC and WHO treatment guidelines for gonorrhoea recommend dual therapy incorporating 
azithromycin (1g) to reduce the development of resistance in N. gonorrhoeae by providing additional 
microbiological cover should resistance develop.25 3, 4  In G-ToG we found significant rates of 
microbiological failure when using a 1 g dose of azithromycin as part of dual therapy, suggesting that 
the azithromycin component may not achieve this aim, particularly for patients with extra-genital 
infection. 
 
Safety of gentamicin and ceftriaxone 
Both ceftriaxone and gentamicin, when combined with azithromycin, were well tolerated. Nausea was 
the most common side effect occurring in 12% of participants receiving ceftriaxone/azithromycin and 
14% for gentamicin/ azithromycin. Nausea and vomiting are uncommon side effects of ceftriaxone 
(incidence ≥ 1/1000 - < 1/100) and have been reported in association with gentamicin, but are common 
following use of oral azithromycin (≥1/100 to <1/10).26 It is therefore likely that the gastrointestinal 
side effects reported were principally caused by azithromycin although the higher reported rate of 
vomiting in those receiving gentamicin (4% cf. 1% for ceftriaxone) suggests that it may also have been 
a contributing factor. Gentamicin was associated with more injection site pain than ceftriaxone (mean 
VAS 36 compared to 21) which took longer to resolve (median 1.5 hours compared to 1 hour), and was 
probably related to the larger volume of injection (6mls for gentamicin vs 2mls for ceftriaxone) and the 
local anaesthetic effect of lidocaine as the dissolving agent for ceftriaxone. 
 
Gentamicin is potentially vestibulotoxic, and can cause dizziness, ataxia and nystagmus. Most previous 
gentamicin studies have evaluated a prolonged course of treatment and the safety of a single dose is 
less well characterized, but a recent systematic review of single dose therapy found vestibulotoxicity to 
be rare27 which is consistent with our findings. Gentamicin can also cause renal impairment following 
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re-uptake of the drug in the proximal renal tubule where it is concentrated. A transient rise in creatinine 
is common when single dose gentamicin is used as antibiotic prophylaxis in elderly, surgical patients27 
but this is less likely to occur in younger, healthier individuals, and little change in the eGFR was 
found in G-ToG participants (-1.4 ml/min [IQR -6.9, 3.8]).  
 
Gentamicin Resistance 
The mechanisms for development of gentamicin resistance are not fully understood but may include 
decreased cell membrane permeability and modification of the drug by cellular enzymes.28 In vitro 
measurement of the MIC provides a phenotypic assessment of antimicrobial susceptibility but the 
‘breakpoint’ MIC value, below which clinical cure occurs and above which gentamicin is ineffective, 
has not been established. The penetration of gentamicin into rectal and pharyngeal tissue is not known 
but has been reported to be suboptimal in the pharynx for spectinomycin, which belongs to a similar 
antibiotic class.25 It has been tentatively suggested that an isolate with an MIC < 8 mg/L is susceptible, 
MIC 8-16 mg/L is intermediate and MIC > 16 mg/L is resistant.29 The European Network for Sexually 
Transmitted Infection Surveillance found that 95% of isolates had gentamicin MICs in the range 4-8 
mg/L12 which is similar, after accounting for differences in testing methodology, to G-ToG participants 
where 74% of isolates had an MIC of 4-8 mg/L. The MIC in GToG participants was not, however, 
predictive of treatment failure with only three isolates having an MIC > 4 mg/L, all of which were 
cleared. Of those isolates with an MIC of 4 mg/L treated with gentamicin, 12(13%) failed therapy 
compared to 81(87%) which were cleared. It is possible that a higher dose of gentamicin would be 
more effective although the limited association between the gentamicin MIC and clinical response does 
not directly support this. 
 
Drug Interactions 
An antagonistic interaction between gentamicin and azithromycin could potentially reduce the efficacy 
of the combination. However, in vitro testing does not suggest either antagonism or synergy,30 and the 
potential for a high cure rate using this regimen in genital infections diagnosed by culture has been 
demonstrated15. A clinically important interaction between the two agents is therefore unlikely. 
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Trial Design 
The G-ToG trial had a robust design resulting in well-balanced treatment arms and a low risk of bias. 
The trial was appropriately powered, pragmatic in design and likely to be relevant to clinical practice in 
the UK and other countries with similar health care systems. It included symptomatic and 
asymptomatic patients, a wide age range, HIV-positive and negative individuals, men and women, 
heterosexual men and MSM, both genital and extra-genital infections, and a wide variety of ethnic 
groups.  The distribution of age, gender, ethnicity and sites of infection for participants in GToG were 
comparable to those in the UK Gonoccocal Resistance to Antimicrobials Surveillance Programme 
(https://www.gov.uk/government/publications/gonococcal-resistance-to-antimicrobials-surveillance-
programme-grasp-report) suggesting that our results are widely applicable.  
 
Unexpectedly, a number of patients who were recruited to the trial were found to have a negative 
NAAT at their baseline visit (ceftriaxone arm  n=46 and gentamicin arm n=39) despite having been 
tested previously and found to be positive, and being recalled to the clinic to be given antibiotic 
treatment. In routine clinical practice a repeat NAAT would not be performed prior to treatment. The 
apparent spontaneous reversion from positive to negative NAAT observed in these trial participants 
could have resulted from an initial false positive NAAT prior to trial entry, a false negative NAAT at 
the baseline trial visit, or natural clearance of gonorrhoea without antibiotic therapy. A previous large 
study has reported spontaneous clearance of pharyngeal gonorrhoea in 6% (139/2204) of patients 
which would be consistent with our findings.31  However, even though NAATs for N. gonorrhoeae 
have high sensitivities and specificities we cannot exclude the possibility of some false 
positive/negative results especially when testing a low prevalence population. The occurrence of 
negative tests in some patients at their baseline visit does not bias our results since they were equally 
distributed between the treatment arms, and a secondary sensitivity analysis excluding these 
participants (risk difference -7.1%, [-11.4%, -2.8%]) was consistent with the primary ITT analysis. The 
NAAT test can remain positive for several days following effective treatment of gonorrhoea but the test 
of cure was taken at least 14 days after receiving antibiotics in accordance with UK national guidance, 
to minimise this possibility. In addition, due to the randomised trial design, a false positive test of cure 
would not bias our results. 
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In conclusion we found that gentamicin plus azithromycin cannot be considered to be non-inferior to 
ceftriaxone plus azithromycin, with a relatively high treatment failure rate occurring in patients with 
extra-genital gonorrhoea. Gentamicin cannot therefore be recommended to replace ceftriaxone as first 
line therapy for gonorrhoea. However, gentamicin combined with 1g azithromycin achieved a cure rate 
of 94% for genital gonorrhoea and its use may be appropriate in patients who are allergic, intolerant or 
harbour a ceftriaxone resistant infection. A 1 g dose of azithromycin as a component of dual therapy 
for gonorrhoea had limited efficacy in treating gentamicin-resistant infections and this suggests that its 
widespread use in other combination regimens to prevent the development of resistance requires 
review. 
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